Working Together for Better Health Partnering with Boehringer Ingelheim. JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017

Transcription

1 Working Together for Better Health Partnering with Boehringer Ingelheim JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017

2 Welcome to Partnering with Boehringer Ingelheim Our guiding principle Value through Innovation A track record of innovation from our own research portfolio as well as from partnered projects A progressive research strategy positions us for the future of healthcare Increased emphasis on partnering and external innovation at all stages of research and development allows us to mature the most creative ideas and pioneer emerging fields of medicine Significant investment in early-science collaborations 2

3 Boehringer Ingelheim in Brief Family-owned global corporation dedicated to Value through Innovation since 1885 Focus on Human Pharmaceuticals, Animal Health and Biopharmaceutical Contract Manufacturing Around 45,700 employees worldwide ~8000 staff in research, development and medicine Four major Human Pharma R&D sites worldwide - Germany, USA, Austria, Japan 2016: 15.9 billion EUR Net Sales (+7.3%) - Thereof, 12 billion EUR in Human Pharma Strong commitment to R&D investment billion EUR (+3.6%) in

4 Successfully delivering innovation for patients A track record of innovation excellence extending over 130 years Products such as OFEV (nintedanib) and JARDIANCE (empagliflozin) maintain our tradition of developing treatments that create new reference points in drug therapy Unprecedented success in recent years: 14 products approved 1 since 2014, including 4 new medical entities 4 Breakthrough Therapy designations 2 Extensive portfolio of successful innovations including SPIRIVA (tiotropium bromide) 1. Approved by the US FDA and/or the EMA 2. Since the inception of the classification in

5 Developing the Next Generation of Medical Breakthroughs Building on our strengths in our core therapeutic areas: CardioMetabolic diseases Central nervous system diseases Immunology and respiratory diseases Cancer research Cancer immunology Creating synergies by identifying and exploring unifying scientific platforms and enabling technologies with potential across our therapeutic areas Immune modulation Harnessing emerging science to develop treatments that create new reference points for and beyond our therapeutic areas 5

6 CardioMetabolic Disease Research Innovation in CardioMetabolic disease research has resulted in important achievements in recent years, especially in thromboembolic diseases and type 2 diabetes Current research aims to meet key unmet needs in: Type 2 diabetes Micro and macrovascular complications of type 2 diabetes, with a focus on chronic kidney diseases and diabetic nephropathy as well as diabetic retinopathy Non-alcoholic steatohepatitis (NASH) and liver fibrosis Obesity Research centers located in USA and Germany 6

7 CNS Disease Research Development of new treatment options for CNS diseases is a key priority targeting high unmet needs across a range of neuropsychiatric disorders Approach focuses on investigating maladaptive brain circuitry underlying major untreated neuropsychiatric symptoms. In addition, pathological underpinnings of circuit malfunction in conjunction with emerging GWAS* data are applied to find ways for early intervention of neuropsychiatric disorders: Cognition focusing on episodic, working memory and/or cognitive control Positive valence focusing on anhedonia/motivation Negative valence focusing on loss/sustained threat Research center in Germany *Genome-wide association studies 7

8 Immunology and Respiratory Disease Research Immunology and Respiratory research combines longstanding leadership in respiratory diseases with the proven ability to address unmet needs in immunemediated diseases. Focus on core scientific themes to arrest the natural history of chronic inflammatory and autoimmune diseases: Mucosal barrier injury and repair Aberrant tissue remodeling Novel approaches to regulate innate & adaptive immune responses Research centers located in USA and Germany 8

9 Cancer Research Commitment to innovation has resulted in key advances in the treatment of lung cancers. Our strategy is to develop therapies for cancers that are dependent on oncogenic drivers that regulate cell growth, survival and fate. Current focus on pathways acting across cancer types: Restraining uncontrolled growth (receptors and intracellular signaling e.g. KRAS) Correcting aberrant developmental pathways (e.g. Wnt signaling) Re-establishing cell death Restoring transcriptional and epigenetic control Research center located in Austria 9

10 Cancer Immunology Research The ability to modulate the body s own immune system has revealed compelling new ways to treat cancer. Our aim is to provide benefit to patients by leveraging tumorand immune-targeting combination approaches. Our current focus areas in cancer immunology: Improve T cell priming: Vaccines, oncolytic viruses, myeloid activation Redirect T cells to the cancer cell: Tumor antigens and T-cell engagers Immune activation within the tumor: Immune regulatory receptor modulators affecting T cells and myeloid cells Research centers located in USA, Austria and Germany 10

11 Immune Modulation Research Understanding fundamental immune mechanisms to discover new treatments across our therapy areas, especially cancer, respiratory and inflammatory diseases. Immune regulation and resetting: Restoring adaptive immune homeostasis and overcoming immune suppression Innate immunity and immune priming: Restoring innate immune homeostasis especially focused to reversing myeloid cell suppression Immune regulatory receptors: Foundational biology as a key drug target class Research centers located in USA and Germany 11

12 Research Beyond Borders Regenerative medicine Gene therapy Research Beyond Borders seeks to push the boundaries of innovation in indications with high medical need within and beyond the therapeutic areas Exploring emerging science and pioneering new therapeutic modalities for and beyond our core therapeutic areas Current research efforts focus on the innovations of the future in areas of high unmet medical need Working with innovation-partners around the world and leveraging ground-breaking science wherever it is found Microbiome New directions 12

13 Our Business of Innovation R&D Strategy Working Together 13

14 Our Innovation Equation Positions us to meet the scientific challenges of the future: Patients whose needs motivate us Outstanding teams with bench to bedside experience A track record of scientific excellence A global community of dedicated scientists and partners whose insights inspire us 14

15 Partnerships: A Key Dimension of our Innovation Equation Partnering plays a strategic role in our drug discovery and development efforts A long-term commitment to invest in the life-science innovation community Partnering opportunities across the drug discovery and development value chain An emphasis on early-science collaborations 50% of our pipeline is anchored in external collaborations 15

16 Working Together for Better Health External innovation is a key component of our research strategy Academia Crowdsourcing Pharma and Biotech Companies Public-Private Consortia 16

17 Some recent partnering highlights Peking University: Collaboration to jointly advance early scientific innovation across a range of areas of high unmet medical need ViraTherapeutics: joint development of a next-generation oncolytic virus therapy platform and investigation of ViraTherapeutics lead candidate Vesicular Stomatitis Virus glycoprotein Saniona: identification of compounds capable of restoring brain network activity in patients with schizophrenia Inventiva: discovery of new medicines for the treatment of IPF and other fibrotic diseases AbbVie: global collaboration to develop and commercialize promising compounds for immunology indications Gubra: Collaboration to identify and develop novel peptide compounds for the treatment of obesity 17

18 Our Partnering Focus CardioMetabolic Diseases Central Nervous System Diseases Immunology Oncology & Cancer Immunology For more information please visit: Respiratory Diseases Research Beyond Borders Technologies For presentation purposes only. Not for distribution. 18

19 Expanding our Global Community of Innovation Partners A long-term commitment to invest in the life-science innovation community: Joint partnerships with academia and industry are the cornerstone of our scientific relationships Committed to support open-source science through involvement in public-private partnerships Pioneering new ways of collaborating including problemsolving through scientific crowdsourcing Corporate Venture Fund drives early-stage innovation through investments in biotechnology and start-up companies 19

20 Project-Centric Transaction Strategies We seek to create an agreement that meets our mutual needs and facilitates success for our project As a family-owned company with a heritage of 130 years, we have a track record of Long-term sustained performance Commitment to a long-term research and investment focus to nurture the next generation of medical breakthroughs equally extends to our partnerships Investing in enduring partnerships that create a culture for shared success 20

21 Capabilities to Complement your Expertise Research Global research & development presence Research sites in key locations in Europe, North America and Asia Clinical Trials 1 1,350 studies 640,000 patients Market Access Experienced market access team Integrated part of the R&D, marketing and regulatory teams Clinical Development Dedicated phase 1 clinical unit Regulatory 14 products approved since o 4 new medical entities 2 o 4 breakthrough therapy designations 3 Sales & Marketing Effectively translates R&D achievements into brand successes 1. In the 10 years Approved by the US FDA and/or the EMA 3. Since the inception of the classification in

22 Working Together for Better Health A unique culture of innovation based on our people, our focus on patients and our breakthrough science Commitment to long-term research and sustained investment focus extending equally to our alliances Enduring relationships with our partners built on our company values: respect, empathy, trust, passion A passion for science that encourages us each day to explore further and work harder to discover and develop new medicines Partnership success that is the result of brilliant diverse minds working together to unlock innovation and create new channels of discovery 22

23 Working Together for Better Health Partnering with Boehringer Ingelheim